October 13, 2018

CDXC: ChromaDex Corporation Stock

by Wilton Risenhoover

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M)	584.08
Enterprise Value ($M)	551.83
Book Value ($M)	34.37
Book Value / Share	0.45
Price / Book	16.99
NCAV ($M)	29.98
NCAV / Share	0.39
Price / NCAV	19.48

Profitability (mra)
Return on Invested Capital (ROIC)	0.04
Return on Assets (ROA)	0.03
Return on Equity (ROE)	0.05

Liquidity (mrq)
Quick Ratio	2.35
Current Ratio	2.95

Balance Sheet (mrq) ($M)
Current Assets	52.13
Assets	56.52
Liabilities	22.15
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	0.00
Net Income	0.00
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
08-21	13D/A	Prime Tech Global Ltd	0.00
08-21	13D/A	Pioneer Step Holdings Ltd	25.41	144.68

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-10-31	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-
2024-08-07	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number: 001-37752
2024-05-08	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number: 001-3775
2024-03-06	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-22	152,904	1,021,474	14.97
2024-11-21	235,006	968,161	24.27
2024-11-20	114,338	545,191	20.97
2024-11-19	271,453	1,104,250	24.58
2024-11-18	239,230	1,382,731	17.30
(click for more detail)

Similar Companies
CDIO – Cardio Diagnostics Holdings, Inc.	CDMO – Avid Bioservices, Inc.
CDTX – Cidara Therapeutics, Inc.	CELU – Celularity Inc.
CELZ – Creative Medical Technology Holdings, Inc.

Financial data and stock pages provided by
Fintel.io

Related